Dr. Jhaveri Discusses a Basket Trial of Taselisib in Solid Tumors

Komal L. Jhaveri, MD, FACP
Published: Wednesday, Aug 29, 2018



Komal L. Jhaveri, MD, FACP, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses a basket trial of taselisib in patients with PIK3CA-mutated locally advanced or metastatic solid tumors.

Jhaveri says that taselisib is a potent, selective, oral inhibitor of class I PI3Kα, γ, and δ isoforms. In a phase I basket study (NCT01296555), the PI3K inhibitor taselisib was given to patients with PIK3CA-mutated solid tumors who had progressed after, or did not response to, at least 1 prior treatment.

There are 11 cohorts of patients with various solid tumors in the basket trial including endometrial, bladder, head and neck squamous cell carcinoma, cervical, gastric or gastroesophageal junction, small cell lung, triple-negative breast, colorectal, squamous, ovarian, and patients with tumors not otherwise specified. Patients on the study received either 4 mg or 6 mg of taselisib daily. The primary endpoint is safety and tolerability, with a secondary endpoint of antitumor activity.
SELECTED
LANGUAGE


Komal L. Jhaveri, MD, FACP, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses a basket trial of taselisib in patients with PIK3CA-mutated locally advanced or metastatic solid tumors.

Jhaveri says that taselisib is a potent, selective, oral inhibitor of class I PI3Kα, γ, and δ isoforms. In a phase I basket study (NCT01296555), the PI3K inhibitor taselisib was given to patients with PIK3CA-mutated solid tumors who had progressed after, or did not response to, at least 1 prior treatment.

There are 11 cohorts of patients with various solid tumors in the basket trial including endometrial, bladder, head and neck squamous cell carcinoma, cervical, gastric or gastroesophageal junction, small cell lung, triple-negative breast, colorectal, squamous, ovarian, and patients with tumors not otherwise specified. Patients on the study received either 4 mg or 6 mg of taselisib daily. The primary endpoint is safety and tolerability, with a secondary endpoint of antitumor activity.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Defining New Roles for the Application of PARP Inhibition Strategies in Multiple Tumor TypesDec 31, 20181.5
Oncology Briefings™: New Frontiers in the Treatment of MSI High Endometrial CancerDec 31, 20181.0
Publication Bottom Border
Border Publication
x